CoagulationDisorders near Montvale, NJ

Biography: Dr. Lisa Roth is an Assistant Professor in the Departments of Pediatrics and Medicine at Weill Cornell Medicine. She is also the Director of the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Roth has been named the Charles, Lillian, and Betty Neuwirth Clinical Scholar in Pediatric Oncology. Dr. Roth completed her undergraduate work at Duke University. She received her medical degree from New York University School of Medicine. Dr. Roth conducted her residency at NewYork-Presbyterian/Weill Cornell and her fellowship in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian where she served as chief fellow. Dr. Roth specializes in treating children, adolescents and young adults with lymphoma and leukemia. She is a member of the Children's Oncology Group and an active participant in Hodgkin lymphoma and non-Hodgkin lymphoma clinical trials. She is also a member of the Weill Cornell Center for Lymphoma, a group which is internationally recognized for it's leadership in the treatment of patients with lymphoma. Dr. Roth's research focuses on identifying new treatments for children with lymphoma. She is particularly interested identifying novel targeted therapies. Targeted therapies may be less toxic than conventional chemotherapy and may be able to rescue those patients with chemotherapy-resistant disease. Dr. Roth has been recognized for her work with awards from the National Institutes of Health (NIH), the Lymphoma Research Foundation, Hyundai Hope on Wheels Foundation, and the St. Baldrick's Foundation. For More Videos, please see below: OR-Live: Treating AYA Patients with Hodgkins Lymphoma (5/10/2017)https://www.youtube.com/watch?v=PT-Qwg2EvqgLymphoma Cancer Treatment NY - Weill Cornell Dr. Roth In the News: Taking Away the Toll (12/2015)http://www.nyrr.org/races-and-events/2016/nyrr-new-york-mini-10k/lisa-roth

Biography: Dr. Ran Reshef trained in Hematology, Oncology, and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is the Clinical Lead for the CAR-T Cell Program at Columbia, a principal investigator at the Columbia Center for Translational Immunology, and a member of the Herbert Irving Comprehensive Cancer Center.

Biography: Diane George, MD cares for children and adolescents undergoing stem cell transplantation as a treatment for cancer (particularly leukemia and lymphoma), noncancerous blood disorders (like sickle cell anemia), and immunodeficiencies. She specializes in transplantation for patients who don't have a related bone marrow donor, and also takes care of patients undergoing autologous stem cell transplantation for solid tumors. Dr. George was originally attracted to the field of pediatric oncology because she wanted to take on the challenge of fighting pediatric cancer, and stem cell transplantation offers the ultimate cure in select patients. It is a complex medical field, and Dr. George enjoys being able to take care of children with complex medical conditions. Dr. George also conducts clinical research. She is currently evaluating a procedure called "CD34-selected stem cell transplantation" to remove T-cells from donor bone marrow. This approach reduces the risk of graft-versus-host disease (GVHD) - a potential complication of bone marrow transplantation in which T-cells from the donor attack the tissue of the recipient. This approach benefits patients who do not have a well-matched family donor, and it could potentially make bone marrow transplantation an option for more patients. Dr. George is also interested in studying how a patient's immune system rebuilds itself after CD34-selected stem cell transplantation. At NewYork-Presbyterian/Morgan Stanley Children's Hospital, every member of a child's healthcare team shares the same compassion and dedication to helping them get well. Dr. George looks forward each day to the camaraderie, intellectual stimulation, and problem-solving she shares with fellow team members. After being in the field for more than 20 years, Dr. George uses the knowledge and experience she has gained to benefit patients and their families.

Biography: Dr. Lyndon Kim, MD is a Hematology Specialist who practices in New York, NY. He is 71 years old and has been practicing for 40 years. Dr. Lyndon Kim, MD is affiliated with Mount Sinai Morningside and Mount Sinai Hospital.

Care Philosophy: I treat each person as a unique individual. I get to know that person and listen to the medical issue(s) that led him/her to see me. I spend time in conversation and examination to gather the information necessary for a diagnosis and treatment. I discuss the management options so that we can jointly select the appropriate treatment. Every question is welcomed. I enjoy learning about each person and sharing the benefit of my expertise. I hold sacred the trust placed in my care.

Biography: Dr. Iwamoto is a neuro-oncologist whose previous training includes a neurology residency at NewYork-Presbyterian/Weill Cornell Medical Center and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. For over three years, Dr. Iwamoto was an attending physician and an investigator at the Neuro-oncology Branch, a trans-institute branch of the National Cancer Institute and National Institute of Neurological Disorders and Stroke, in Bethesda, MD. At the intramural NIH, Dr. Iwamoto was a principal investigator in early phase clinical trials for brain tumors and worked with laboratory and computational scientists on several translational projects in brain tumors. Dr. Iwamoto was recruited to Columbia University as the Deputy Director of the Neuro-oncology Division and is actively developing the clinical and translational research components of this program. He is an expert in the diagnosis, management, and treatment of brain and spinal cord tumors as well as neurological complications of cancer.

Biography: Anna Pavlick, BSN, MSc, DO, MBA is a medical oncologist with over 20 years of experience treating patients with skin cancer, including melanoma, basal cell cancer,squamous cell cancer and Merkel cell carcinoma. She is also an expert in treating ocular melanoma, eyelid tumors and other rare solid tumor malignancies, including a research interest in neurofibromatosis-1 (NF1) malignancies. She is currently accepting new patients for both in-office visits and telehealth appointments.Dr. Pavlick was recruited to Weill Cornell Medicine as Professor of Medicine in the Division of Hematology & Medical Oncology. She is the founding Director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian. Dr. Pavlick's major research interests include investigating targeted therapies, combination therapies and immunotherapies. She also conducts outcomes research evaluating quality of life.Dr. Pavlick earned her medical degree from the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School; her Master of Science in Human Anatomy from Fairleigh Dickinson University; and her Bachelor of Science in Biology and Nursing degree from Fairfield University. She completed an internal medicine residency at UMDNJ and hematology and oncology fellowship training at Memorial Sloan Kettering Cancer Center. In addition to her undergraduate and medical training, Dr. Pavlick graduated from the Drexel School of Medicine Executive Leadership in Academic Medicine in 2012 and earned her Master of Business Administration (MBA) degree from Columbia University Business School in 2017.Dr. Pavlick has authored and co-authored over 100 publications and presented her research at international meetings. She serves on the several editorial boards, including The Journal of Drugs in Dermatology and The Journal of ImmunoTherapeutics of Cancer (Associate Editor). She is a member of leading oncology societies including American Society of Clinical Oncology (ASCO), American Academy of Clinical Research (AACR), the Society for Melanoma Research, Society for Immunotherapy and Translational Research in Cancer and the European Society of Medical Oncology (ESMO).

Biography: James McKiernan, MD, is the John K. Lattimer Professor of Urology, and CEO, of ColumbiaDoctors. He also is the interim dean of Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues. For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer.